United Kingdom

Time filter

Source Type

News Article | May 1, 2017
Site: news.yahoo.com

Here's a quick rundown of how some of the industry's largest players' stock prices have performed over the trailing 12 months. This article originally appeared on the Motley Fool. The marijuana industry is the hottest thing since sliced bread, and marijuana stocks are thriving as a result. Here's a quick rundown of how some of the industry's largest players' stock prices have performed over the trailing 12 months: And trust me, the list goes on with similar results throughout the entire industry. Also, don't feel sorry for the GW Pharmaceuticals investors who've been "left behind" with only a 35% trailing one-year gain. The stock is up more than tenfold in a span of four years! Marijuana stocks have benefited by the rapid growth of legal pot sales. According to cannabis research firm ArcView, North American legal weed sales grew 34% to $6.9 billion in 2016. What's more, investment firm Cowen & Co. believes that legal pot sales could hit $50 billion by 2026, implying a compound annual growth rate of better than 23% over the next decade. Those are mouthwatering growth rates for businesses and a major attraction for investors. Today, we can add yet another reason why marijuana stocks may keep drawing in new investors: a new, and highly favorable, cannabis survey. According to a brand-new poll from CBS News, which had more than 1,000 people surveyed by phone between April 11 and April 15, 61% of Americans now support the legalization of weed compared to 33% who believe it should be illegal. The 61% support represents an all-time high, and is up 5% from last year, 8% from 2015, 10% from 2014, and 21% from 2011. Also, 88% of respondents would like to see medical cannabis legalized nationally. There were a number of additional intriguing findings from this study. For instance, 53% of respondents believe alcohol is more harmful than marijuana, compared to just 7% who chose marijuana as more dangerous than alcohol. For what it's worth, 28% believed they were equally harmful, and 9% chose neither as harmful. There was also a mixed reaction on whether marijuana use does or doesn't lead to violent crime. In total, 23% said it leads to an increase in violent crime, 22% responded that it leads to a decline in violent crime, and 49% suggested it had no effect. Long story short, we're seeing an all-around softening stance toward marijuana, and that paints an increasingly encouraging picture for marijuana stocks. Since lawmakers are voted in by the public, and a majority of the public now appears to favor the legalization of cannabis, Congress may be forced to act sooner than later to reconsider rescheduling or legalizing pot. Remember, marijuana is a schedule I drug in the U.S., meaning it's illegal and is considered to have no medical benefits. The drugs' current status makes it incredibly difficult for researchers to conduct thorough clinical studies on marijuana's benefits and risks, and it makes life difficult on weed-based businesses. U.S.-based marijuana companies have little to no access to basic banking services, meaning they're forced to deal solely with cash, which is a security concern. They also aren't able to take normal corporate tax deductions due to the fact that they're selling an illegal substance, leading them to pay tax on their gross profits rather than net profits. On one hand, the changing tide of opinion on pot has paved the way to increased sales for a number of marijuana companies. There are now eight states in the U.S. that have legalized recreational weed, and Canada's government may wind up legalizing the sale of recreational marijuana throughout the country by as early as next year. This fairly steady rate of expansion, fueled by changing public opinion on the drug, is why companies like Aurora Cannabis in Canada are undertaking massive capacity expansion projects. Aurora Cannabis is currently constructing the Aurora Sky project which will increase its grow capacity more than eight-fold to nearly 900,000 square feet. Even though Aurora Cannabis is entirely focused on supplying product to the medical marijuana community at the moment, legalizing recreational pot in Canada could quickly change its strategy to an even higher growth revenue channel (recreational sales). But, marijuana stocks mostly remain a double-edged sword for investors. Aside from the fact that well over 90% of pot stocks are unprofitable and may not have sustainable business models, there's a legal mountain that could halt marijuana's expansion in its tracks.


News Article | April 19, 2017
Site: www.biosciencetechnology.com

Promising results from a large-scale, controlled, Phase 3 clinical study of epilepsy patients being treated with cannabidiol will be presented April 25 at the American Academy of Neurology’s Annual Meeting in Boston. GW Pharmaceuticals’ liquid oral formulation of cannabidiol (CBD), called Epidiolex, is one of 500 compounds found in cannabis. Unlike the well-known compound, tetrahydrocannabinol (THC), CBD does not produce a “high” as the psychoactive component is absent. Results from the randomized, double-blind, placebo-controlled study found that almost 40 percent of people with Lennox-Gastaut syndrome (LGS) had at least a 50 percent reduction in drop seizures, compared to 15 percent taking a placebo. LGS is a severe form of epilepsy that often results in impaired intellectual development and does not usually respond well to medications. “Our study found that cannabidiol shows great promise in that it may reduce seizure that are otherwise difficult to control,” study author Anup Patel, M.D., of Nationwide Children’s Hospital and The Ohio State University College of Medicine said in a prepared statement. The study involved 225 people, who for 14 weeks received either a daily higher dose of cannabidiol, a lower dose, or a placebo in addition to their current medications. The average age of participants was 16, and prior to the study all had an average of 85 drop seizures per month.  On average, participants had already tried six epilepsy drugs that were not successful, and continued to take about three epilepsy drugs during the study. Those taking the higher 20 mg/kg daily cannabidiol dose saw an overall 42 percent decrease in drop seizures. For 40 percent of the participants, seizures were reduced by 50 percent or more. Participants receiving the lower 10 mg/kg dose, saw an overall 37 percent decrease in drop seizures. A reduction of 50 percent or more was seen in 36 percent of patients. Comparatively, the placebo group experienced a 17 percent decrease in drop seizures, and seizures were cut in half or more for 15 percent of the participants. Side effects were more common in the higher dose groups, with 94 percent compared to 72 percent in those taking the placebo, but most were mild to moderate.  Decreased appetite and sleepiness were the two most common side effects. Participants receiving the CBD were more likely to report an improvement in overall condition, with 66 percent saying they had improved, compared to 44 percent of patients in the placebo group. “Our results suggest that cannabidiol may be effective for those with Lennox-Gastaut syndrome in treating drop seizures,” Patel said. “This is important because this kind of epilepsy is incredibly difficult to treat. While there were more side effects for those taking cannabidiol, they were mostly well-tolerated. I believe that it may become an important new treatment option for these patients.” A New Drug Application is expected to be submitted to the Food and Drug Administration later this year.


News Article | April 20, 2017
Site: www.marketwired.com

DENVER, CO--(Marketwired - Apr 20, 2017) - Hemp Business Journal, the leading provider of data and market intelligence for the hemp industry, has published estimates of the size of the 2016 U.S. retail market for hemp products. Hemp Business Journal and Vote Hemp estimate the total retail value of hemp products sold in the U.S. in 2016 was $688 million. Items like shelled seed, protein powder, soaps and lotions have continued to increase complemented by successful hemp cultivation pilot programs in numerous states. In all, sales of Hemp CBD products boosted the industry to a five year 22% CAGR. Of the $688 million market size, Hemp Business Journal analyzed the market across seven primary product categories: (1) Food (2) Personal care (3) Textiles, (4) Supplements, (5) Hemp derived Cannabidiol (CBD), (6) Industrial Applications such as car parts, and (7) Other Consumer Products such as paper and construction materials. Further data and market intelligence will be published in the State of Hemp Market Report 2017 in the months to come following completion of Hemp Business Journal's industry-wide survey. The growth of Hemp CBD -- a category with $130 million in sales and growing at a 53% AGR -- contributed significantly to the $688 million in total sales. Hemp Business Journal reports the Hemp CBD category was led by channel sales in natural and specialty products, smoke shops, and online verticals. CBD-based pet care products are a 'growth category to watch' in 2017. SPINS, the leading market research firm for natural products, tracked $2,470,000 for products with CBD listed as the primary ingredient in 2016. Retail sales leaders in the CBD Hemp category for 2016 included CV Sciences, Bluebird Botanicals, CW Hemp, Mary's Nutritional, and Liberty Lotions, among others. Pharmaceutical companies continued progress to develop innovative cannabinoid based drugs. In the U.S., GW Pharmaceuticals has received Orphan Drug Designation from the FDA for its CBD based drug, Epidiolex, in the treatment of LGS, Dravet syndrome, Tuberous Sclerosis Complex, and Infantile Spasms, each of which are severe infantile-onset, drug-resistant epilepsy syndromes. Sales of Epidiolex are slated to begin in 2018 or 2019, and are projected by Hemp Business Journal to reach $120 million by 2020. If HBJ forecasts for Epidiolex prove accurate, sales of the drug will represent nearly 7% of total hemp industry sales by 2020 -- an estimated $1.8 billion market. "Hemp Business Journal estimates the total retail value of all hemp products sold in the U.S. to be at least $688 million for 2016. We estimate the hemp industry will grow to $1.8 billion in sales by 2020, led by hemp food, body care, and CBD-based products. The data demonstrates the hemp industry is growing quickly at 22% five year CAGR and being led by food and body care products, with Hemp CBD products showing a 53% AGR," said Sean Murphy, the Founder and Publisher of Hemp Business Journal. Eric Steenstra, President of Vote Hemp continued, "To date, 31 states have passed legislation that allows hemp farming per provisions set forth in the 2014 Farm Bill, and the U.S. remains the largest consumer market for hemp products worldwide. We need Congress to pass federal legislation to allow commercial hemp farming nationally, to let our farmers and American business take advantage of the robust economic opportunity hemp provides." Hemp data charts, research and market intelligence are available on HempBizJournal.com and will be published in Hemp Business Journal's comprehensive annual market report, The State of Hemp 2017. The market report is currently available for pre-order on Hemp Business Journal's website.


BOSTON - Taking cannabidiol may cut seizures in half for some children and adults with Lennox-Gastaut syndrome (LGS), a severe form of epilepsy, according to new information released today from a large scale controlled clinical study that will be presented at the American Academy of Neurology's 69th Annual Meeting in Boston, April 22 to 28, 2017. Cannabidiol is a molecule from the cannabis plant that does not have the psychoactive properties that create a "high." Nearly 40 percent of people with LGS, which starts in childhood, had at least a 50 percent reduction in drop seizures when taking a liquid form of cannabidiol compared to 15 percent taking a placebo. When someone has a drop seizure, their muscle tone changes, causing them to collapse. Children and adults with LGS have multiple kinds of seizures, including drop seizures and tonic-clonic seizures, which involve loss of consciousness and full-body convulsions. The seizures are hard to control and usually do not respond well to medications. Intellectual development is usually impaired in people with LGS. Although the drop seizures of LGS are often very brief, they frequently lead to injury and trips to the hospital emergency room, so any reduction in drop seizure frequency is a benefit. "Our study found that cannabidiol shows great promise in that it may reduce seizures that are otherwise difficult to control," said study author Anup Patel, MD, of Nationwide Children's Hospital and The Ohio State University College of Medicine in Columbus and a member of the American Academy of Neurology. For the randomized, double-blind, placebo-controlled study, researchers followed 225 people with an average age of 16 for 14 weeks. The participants had an average of 85 drop seizures per month, had already tried an average of six epilepsy drugs that did not work for them and were taking an average of three epilepsy drugs during the study. Participants were given either a higher dose of 20 mg/kg daily cannabidiol, a lower dose of 10 mg/kg daily cannabidiol or placebo as an add-on to their current medications for 14 weeks. Those taking the higher dose had a 42 percent reduction in drop seizures overall, and for 40 percent, their seizures were reduced by half or more. Those taking the lower dose had a 37 percent reduction in drop seizures overall, and for 36 percent, seizures were reduced by half or more. Those taking the placebo had a 17 percent reduction in drop seizures, and for 15 percent, seizures were reduced by half or more. There were side effects for 94 percent of those taking the higher dose, 84 percent of those taking the lower dose and 72 percent of those taking placebo, but most side effects were reported as mild to moderate. The two most common were decreased appetite and sleepiness. Those receiving cannabidiol were up to 2.6 times more likely to say their overall condition had improved than those receiving the placebo, with up to 66 percent reporting improvement compared to 44 percent of those receiving the placebo. "Our results suggest that cannabidiol may be effective for those with Lennox-Gastaut syndrome in treating drop seizures," said Patel. "This is important because this kind of epilepsy is incredibly difficult to treat. While there were more side effects for those taking cannabidiol, they were mostly well-tolerated. I believe that it may become an important new treatment option for these patients." There is currently a plan to submit a New Drug Application to the FDA later this year. The study was supported by GW Pharmaceuticals, developer of cannabidiol. In the United States, GW operates as Greenwich Biosciences Inc. Learn more about epilepsy at http://www. . The American Academy of Neurology is the world's largest association of neurologists and neuroscience professionals, with 32,000 members. The AAN is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer's disease, stroke, migraine, multiple sclerosis, concussion, Parkinson's disease and epilepsy. For more information about the American Academy of Neurology, visit http://www. or find us on Facebook, Twitter, Google+, LinkedIn and YouTube. Dr. Patel will present his findings at 5:45 p.m. ET, on Tuesday, April 25, 2017, in Room 210AB of the Boston Convention and Exhibition Center. Please contact Renee Tessman, rtessman@aan.com, to schedule an advance interview. To access Non-Emerging Science abstracts to be presented at the 2017 AAN Annual Meeting, visit https:/ . Emerging Science abstracts are embargoed until 12:01 a.m., ET, Friday, April 21, 2017, unless otherwise noted by the Academy's Media and Public Relations Department.


When someone has a drop seizure, their muscle tone changes, causing them to collapse. Children and adults with LGS have multiple kinds of seizures, including drop seizures and tonic-clonic seizures, which involve loss of consciousness and full-body convulsions. The seizures are hard to control and usually do not respond well to medications. Intellectual development is usually impaired in people with LGS. Although the drop seizures of LGS are often very brief, they frequently lead to injury and trips to the hospital emergency room, so any reduction in drop seizure frequency is a benefit. "Our study found that cannabidiol shows great promise in that it may reduce seizures that are otherwise difficult to control," said study author Anup Patel, MD, of Nationwide Children's Hospital and The Ohio State University College of Medicine in Columbus, and a member of the American Academy of Neurology. For the randomized, double-blind, placebo-controlled study, researchers followed 225 people with an average age of 16 for 14 weeks. The participants had an average of 85 drop seizures per month, had already tried an average of six epilepsy drugs that did not work for them and were taking an average of three epilepsy drugs during the study. Participants were given either a higher dose of 20 mg/kg daily cannabidiol, a lower dose of 10 mg/kg daily cannabidiol or placebo as an add-on to their current medications for 14 weeks. Those taking the higher dose had a 42 percent reduction in drop seizures overall, and for 40 percent, their seizures were reduced by half or more. Those taking the lower dose had a 37 percent reduction in drop seizures overall, and for 36 percent, seizures were reduced by half or more. Those taking the placebo had a 17 percent reduction in drop seizures, and for 15 percent, seizures were reduced by half or more. There were side effects for 94 percent of those taking the higher dose, 84 percent of those taking the lower dose and 72 percent of those taking placebo, but most side effects were reported as mild to moderate. The two most common were decreased appetite and sleepiness. Those receiving cannabidiol were up to 2.6 times more likely to say their overall condition had improved than those receiving the placebo, with up to 66 percent reporting improvement compared to 44 percent of those receiving the placebo. "Our results suggest that cannabidiol may be effective for those with Lennox-Gastaut syndrome in treating drop seizures," said Patel. "This is important because this kind of epilepsy is incredibly difficult to treat. While there were more side effects for those taking cannabidiol, they were mostly well-tolerated. I believe that it may become an important new treatment option for these patients." There is currently a plan to submit a New Drug Application to the FDA later this year. The study was supported by GW Pharmaceuticals, developer of cannabidiol. In the United States, GW operates as Greenwich Biosciences Inc. Learn more about epilepsy at www.aan.com/patients. The American Academy of Neurology is the world's largest association of neurologists and neuroscience professionals, with 32,000 members. The AAN is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer's disease, stroke, migraine, multiple sclerosis, concussion, Parkinson's disease and epilepsy. For more information about the American Academy of Neurology, visit http://www.aan.com or find us on Facebook, Twitter, Google+, LinkedIn and YouTube. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cannabis-based-medicine-may-cut-seizures-in-half-for-those-with-tough-to-treat-epilepsy-300441939.html


The global medical marijuana market is expected to reach a value of USD 55.8 billion by 2025 It has been identified that, in 2016, Washington D.C. along with 28 states have legalized marijuana for medical uses. In 2016, states such as Arkansas, Florida, North Dakota, Ohio, and Pennsylvania were approved to use the drug in medical applications such as chemotherapies and pain management. The growing number of states and countries getting approval for using it in therapeutic applications is one of the crucial factors driving the demand over the coming few years. The presence of several regulatory frameworks such as the Medical Marijuana Regulation and Safety Act is indicators of the present demand for the drug in the market. The regulatory framework requires every individual or the company associated such as growers, retail operators, and makers of processed pot products to obtain permission and an annual state license from 2018. An increasing number of issued licenses is also among factors that is expected to drive the market especially after 2018. The increasing interest amongst the academic researchers and healthcare providers regarding the therapeutic uses of marijuana is among the significant factors, which is driving the market over the coming years. Some of its potential therapeutic values are suppression of vomiting & nausea, pain relief, and appetite stimulation. In addition, research states that marijuana is effective in providing relief to the patient suffering from HIV/AIDS, glaucoma, cancer, and multiple sclerosis. The growing number of therapeutic applications of the drug is one of the key factors that is propelling the market over the forecast period. Some of the key players are Cara Therapeutics Inc.; CannaGrow Holdings, Inc.; Cannabis Sativa, Inc.; United Cannabis Corporation; GrowBlox Sciences, Inc.; GW Pharmaceuticals, plc; Lexaria Corp; International Consolidated Companies, Inc. Key Topics Covered: 1 Research Methodology 2 Executive Summary 2.1 Market Snapshot 3 Medical Marijuana Market Variables, Trends & Scope 3.1 Market Segmentation & Scope 3.1.1 Market driver analysis 3.1.2 Market restraint analysis 3.2 Penetration & Growth Prospect Mapping 3.3 Medical Marijuana- SWOT Analysis, by Factor (Political & Legal, Economic and Technological) 3.4 Industry Analysis - Porter's 4 Medical Marijuana Application Estimates & Trend Analysis 4.1 Medical Marijuana Market: Application Movement Analysis 4.2 Chronic Pain 4.3 Arthritis 4.4 Migraine 4.5 Cancer 4.6 Other 5 Medical Marijuana Regional Estimates & Trend Analysis, by Application 6 Competitive Landscape For more information about this report visit http://www.researchandmarkets.com/research/cgdf39/medical_marijuana Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-medical-marijuana-market-2014-2017--2025---analysis-of-chronic-pain-arthritis-migraine--cancer-markets---research-and-markets-300443631.html


LONDON, May 05, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, will present at the Bank of America Merrill Lynch 2017 Health Care Conference on Wednesday, May 17, 2017, at 10:00 a.m. (PDT) at the Encore at the Wynn Las Vegas, Las Vegas, Nev.   A live audio webcast of the presentation will be available through GW’s corporate website in the investor relations section from the investor’s calendar of events page at www.gwpharm.com. A replay will be available soon after the live presentation. Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex® (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis Complex and Infantile Spasms. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in 31 countries outside the United States. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. For further information, please visit www.gwpharm.com.


Russo E.B.,GW Pharmaceuticals
British Journal of Pharmacology | Year: 2011

Tetrahydrocannabinol (THC) has been the primary focus of cannabis research since 1964, when Raphael Mechoulam isolated and synthesized it. More recently, the synergistic contributions of cannabidiol to cannabis pharmacology and analgesia have been scientifically demonstrated. Other phytocannabinoids, including tetrahydrocannabivarin, cannabigerol and cannabichromene, exert additional effects of therapeutic interest. Innovative conventional plant breeding has yielded cannabis chemotypes expressing high titres of each component for future study. This review will explore another echelon of phytotherapeutic agents, the cannabis terpenoids: limonene, myrcene, α-pinene, linalool, β-caryophyllene, caryophyllene oxide, nerolidol and phytol. Terpenoids share a precursor with phytocannabinoids, and are all flavour and fragrance components common to human diets that have been designated Generally Recognized as Safe by the US Food and Drug Administration and other regulatory agencies. Terpenoids are quite potent, and affect animal and even human behaviour when inhaled from ambient air at serum levels in the single digits ng·mL -1. They display unique therapeutic effects that may contribute meaningfully to the entourage effects of cannabis-based medicinal extracts. Particular focus will be placed on phytocannabinoid-terpenoid interactions that could produce synergy with respect to treatment of pain, inflammation, depression, anxiety, addiction, epilepsy, cancer, fungal and bacterial infections (including methicillin-resistant Staphylococcus aureus). Scientific evidence is presented for non-cannabinoid plant components as putative antidotes to intoxicating effects of THC that could increase its therapeutic index. Methods for investigating entourage effects in future experiments will be proposed. Phytocannabinoid-terpenoid synergy, if proven, increases the likelihood that an extensive pipeline of new therapeutic products is possible from this venerable plant. © 2011 The British Pharmacological Society.


The present invention relates to cannabinoids for use in the prevention or treatment of neurodegenerative diseases or disorders. Preferably the cannabinoids are cannabichromene (CBC) cannabidivarin (CBDV) and/or cannabidivarin acid (CBDVA). More preferably the neurodegenerative disease or disorder to be prevented or treated is Alzheimers disease.


The present invention relates to the phytocannabinoid tetrahydrocannabivarin (THCV) for use in the protection of pancreatic islet cells. Preferably the pancreatic islet cells to be protected are beta cells. More preferably the protection of the pancreatic islet cells maintains insulin production at levels which are able to substantially control or improve control of blood glucose levels in a patient.

Loading GW Pharmaceuticals collaborators
Loading GW Pharmaceuticals collaborators